Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
2.20
0.06 (2.80%)
At close: May 29, 2025, 3:56 PM
2.20
0.00%
After-hours: May 29, 2025, 04:00 PM EDT
2.80% (1D)
| Bid | 1.72 |
| Market Cap | 202.75M |
| Revenue (ttm) | 12.62M |
| Net Income (ttm) | -49.47M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -3.19 |
| Forward PE | 5 |
| Analyst | Buy |
| Ask | 2.2 |
| Volume | 10,333 |
| Avg. Volume (20D) | 25,621 |
| Open | 2.20 |
| Previous Close | 2.14 |
| Day's Range | 2.17 - 2.22 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.94 |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
5 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
